The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Subscribe To Our Newsletter & Stay Updated
